Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players

G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences

Franz Faul, Edgar Erdfelder, Albert-Georg Lang et al. · Behavior Research Methods · 2007 · 61K citations · Full text

Behavioral Sciences, Engineering, Social Behavior +9

Decreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis

Philippe Lesnik, Christopher A. Haskell, Israel Charo · Journal of Clinical Investigation · 2003 · 464 citations · Full text

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2

Hyun Jeong Jeong, Hyun‐Sook Lee, Kyung‐Sup Kim et al. · Journal of Lipid Research · 2007 · 345 citations · Full text

Promoter Activity, Oxidative Stress, Metabolic Syndrome +19

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway

Zhi‐Han Tang, Juan Peng, Zhong Ren et al. · Atherosclerosis · 2017 · 269 citations

Inflammation, New Role, Inflammatory Disease +15

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36

Zhiyong Qi, Liang Hu, Jianjun Zhang et al. · Circulation · 2020 · 255 citations